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moxazole and Ciproﬂoxacin. AMR surveillance revealed that
the prevalence of multi-drug resistant (MDR) Salmonella
(resistant to three or more at a time) has been decreas-
ing gradually (30% in 2002, 13%in 2003, 5% in 2004 and 2%
each in 2005 and 2006) in Nepal.
Conclusions: Although the number of MDR Salmonella has
been decreasing in Nepal, the total number of Salmonella
isolates has been increasing. The increasing trend of S.
paratyphi A with high resistance rate of Nalidixic acid can be
regarded as a worrisome situation and may reﬂect the emer-
gence of ﬂuoroquinolone resistance. Continued surveillance
and inclusion of appropriate antimicrobials in the routine
susceptibility testing for Salmonella are necessary in Nepal.
doi:10.1016/j.ijid.2008.05.1091
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Background: The hepatitis B virus (HBV) is an enveloped
DNA virus with an icosahedral capsid replicating via reverse
transcription. The crystal structure of the capsid is known.
The viral envelope contains three different coterminal pro-
teins (S, M, and L proteins) spanning the membrane several
times. Hepatitis B virus large surface protein ‘LHBs’ has
the unusual property of accumulating in a particulate form
within a preGolgi compartment, leading to marked prolifer-
ation of intracellular membranes
Objective: The aim of this study was to investigate the
clinical value of LHBs used for diagnosis of the clinical hep-
atitis B patient and relativity with replication of hepatitis B
virus.
Methods: A total of 600 HBsAg positive patients in
The Fourth people’s hospital of Shenzhen between April-
December 2006 were included to the study. The patients
were classiﬁed into two groups according to their serologi-
cal patterns (Group 1: HBeAg positive 300 cases; Group 2:
HBeAg negative 300 cases). The age and gender distribu-
tions of the groups were similar. HBV serological markers and
LHBs have been detected by Enzyme Linked Immunosorbent
Assay (ELISA), and viral load (HBV-DNA) were investigated
by real-time polymerase chain reaction(PCR)
Results: No signiﬁcant difference of positive rate was
observed between HBV DNA 76.17% (457/600) and LHBs
77.33% (464/600) (X2 = 0.696, P > 0.05) in 600 HBsAg-positive
serum samples; Postive rate of HBV DNA and LHBs were 95.0
(285/300) and 96.0 (288/300) in HBeAg postive samples and
were 57.33 (172/300) and 58.67 (176/300) in HBeAg neg-
ative samples(X20.725, P > 0.05; X20.253, P > 0.05); Serum
LHBs levels were correlated with the serum HBV DNA copies
(r = 0.948).
Conclusion: The results demonstrated that there is a per-
fect correlation between the copies of HBV-DNA and the
levels of LHBs, and LHBs expression can reﬂect the repli-
cation of HBV.
doi:10.1016/j.ijid.2008.05.1092
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Objective: The persistence of Anti-HBc IgM among inac-
tive HBsAg carriers may be with hidden dangers anf forecasts
the existence of liver damage. A trial of lamivudine in such
carriers was carried out for the ﬁrst time in this study.
Patients and Methods: A total of 62 Inactive HBsAg carri-
ers (age range; 25—45 years) with persistence of anti-HBc
IgM were randomized to receive either 100mg lamivu-
dine (32/62) or placebo (30/60) daily for 6 months. The
studied carriers were regular attendees of the Virology
Center in Mosul, North Iraq for follow-up. Enzyme-linked
immunosorbent assay techniques were performed to detect
the different markers of HBV infection
Results: Among the lamivudine group, anti-HBc IgM serol-
clearance rate was 81.3% and HBsAg seroconversion rate was
9.4% compared to 6.3% and 3.3% among placebo group. Num-
ber of adverse clinical events were observed, but were of
mild nature and tolerable by the participants who completed
the study
Conclusions: The trial of lamivudine in this group of
inactive HBsAg carrier state cases proved to be safe and
efﬁcacious.
doi:10.1016/j.ijid.2008.05.1093
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Background: HCV infection is very common in intra-
venous drug usres (IDUs) and it has more often progression
in chronic hepatitis. Inspite of that, just small percent of
these patients with chronic hepatitis C (CHC) is treated with
antiviral therapy. Interruption of therapy was common in
IDUs due to low compliance and adverse reactions, usually
psychiatric.
Methods: This is a 5-year retrospective analysis of 37 IDUs
with CHC who were treated in Institute for Infectious and
Tropical Diseases, Clinical Center of Serbia in Belgrade. HCV
RNA and HCV genotype (G) were determinated by PCR. Liver
biopsy was performed in 34 (91,89%) patients. All 37 patients
were treated with pegilated interferon alpha 2a+ Ribavirin
according to standard protocols
Results: There were 37 IDUs with CHC in the age from
17—54 years. They abused heroin iv for 1—21 years. HCV
infection was diagnosed 1—18 years before treatment. All
patients were HBsAg and anti-HIV negative. 18 patients
(48,64%) also consumed alcohol. AST level ranged from
35—248 IU/L. Liver biopsy showed cirrhosis in 5 (14,7%)
patients and ﬁbrosis in 29 (85,3%) patients. Steatosis was
conﬁrmed in 9 (24,32%) patients. Viral load ranged from
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100.000 to 33.750.000 HCV RNA coppies/mL. HCV genotype
were found: G1 in 19, G2 in 2, G3 in 9, G4 in 2 and mixed G
in 5 patients. Sustained viral response (SVR) was achived in
21/27 (77,77%), relapse (R) was found in 4 (14,81%) patients
and 2 patients (7,40%) were nonresponders (NR). Therapy
was deﬁnitly interrupted in only one patient. We had to stop
treatment temporaly and to reduse dose of antiviral drugs
in 10 (27%) patients. Adverse effects of therapy were found
in 30 (81,1%) patients
Conclusions: Treatment of CHC in IDUs was successful and
it shows that more IDUs should be treated with antiviral
therapy.
doi:10.1016/j.ijid.2008.05.1094
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Background: It is known that the nosocomial viral hepati-
tis agents Hepatitis B (HBV), Hepatitis D (HDV), and Hepatitis
C (HCV) viruses are transmitted by the close contact and
invasive procedures. The nosocomial viral hepatitis (NVH)
transmission cases were followed for last seven years period.
Materials and Methods: Between 1999 to 2006; 28 NVH
cases were followed for 12—72 months at the Research and
Application Hospital that is committed to the University. It
was taken the notice of the negative chronic viral hepatitis
markers and normal value of transaminases of the cases. The
cases that were considered of transmission of HBV, HCV, and
HDV at the outside of the hospital were excluded from the
study. All the cases were evaluated for the acute viral hep-
atitis markers for HBV, HCV and HDV, after 15th and 90th day
of the suspected transmission. The cases who were known
that transmission of HBV, HDV and HCV was occurred were
re-evaluated for the medical status of before transmission
and present.
Findings and Results: There were totally 28 cases (eigh-
teen were man, ten were women) ages between 20 to 67
were suspected of the transmission of nosocomial viral hep-
atitis. Six of them were doctors, six of them were nurses,
four of them were medical stuff and twenty were patients
that were hospitalized for another medical reason. It was
determined that all the hospital stuff had their viral hep-
atitis agent transmission because of needle-sticks and ten
of the patients had their transmission because of endo-
scopic and invasive procedures. From these 28 cases: 5
cases (four medical staff, and one patient) exposured HBV,
previously known 4 chronic hepatitis B patients exposured
nosocomial HDV transmission and 19 cases (6 doctors, 6
nurses, 7 patients) exposured nosocomial HCV transmission.
At the end of the observation; from the 4 medical stuff and
one patient who didn’t get any prophylaxis two of them
got Anti-HBs seroconversion, but the other two stuffs got
their diseases chronically HBV carriers. Four patients who
were previously known that were chronic viral hepatitis B,
acquired their HDV exposure and transmission because of the
endoscopic procedures and superinfection were occurred at
all four of them. These four HDV superinfection patients
were given interferon treatment (10 million IU/3 times a
week) for one year. After the treatment their transami-
nases decreased to the normal values and HDV-RNA of all
four patients were negative. The two of four nosocomially
HDV exposured patients had Anti-HBs seroconversion and all
four patients had negative Anti-HDV tests. After one year,
the two patients who had Anti-HBs seroconversation and got
HBsAg positivity again. HCV exposured 12 items (6 doctors,
6 nurses) got nor transaminase elevation neither Anti-HCV
or HCV-RNA positivity. From the HCV exposured 7 patients;
the two of them got spontaneous clearance, ﬁve of them got
acute HCV infection and treated for one year. But one male
patient with acute HCV infection who didn’t tolerate the
treatment got a decomposed liver disease after two years.
At one acute HCV infected female and spontaneously cleared
patient got a ﬂare of HCV infection during an immunosuppre-
sive treatment because of her temporal arteritis. The other
four patients who had received pegilated interferon treat-
ment for one year got sustained response to the treatment.
Conclusions: As a result from ﬁve nosocomial HBV infec-
tions two had a chronic hepatitis B infection. From 19
nosocomial HCV infection there was one chronical infec-
tion. From four nosocomial HDV infection were treated
successfully. The viral hepatitis agents causes chronic ill-
ness at immun compromised patients. These patients must
be evaluated for prophylaxis after a HBV exposure. Although
HCV is still an important viral pathogen for nosocomial
transmission; it makes chronic viral hepatitis that has long
progression time period at healthy people.
doi:10.1016/j.ijid.2008.05.1095
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Background: Although several blood borne viral infec-
tions are transmitted sexually, yet acquiring hepatitis C virus
(HCV) infection by this route is debated. Risk of chronicity
with HCV infection is high and increases co-morbidity when
present along with HIV in high risk groups.
Methods: We recruited 426 female sex workers (FSWs)
who consented by Respondent Driven Sampling (RDS) tech-
nique in a Linked Anonymous strategy. The respondents
provided behavioral data and biological samples. Serum
samples were tested for HIV and HCV by ELISA. To assess
the associated risk factors, samples were also tested for
HSV-2 and syphilis. Urine samples were tested for gonorrhea
and chlamydial infections by Aptima Gen probe. Data were
analyzed using SPSS 10.0 statistical software.
Results: Of the 426 FSWs enrolled, the overall anti-HCV
antibody positivity was 9.6%; 45.9% among those who were
IDUs and in 7.5% with no history of injecting drug abuse,
blood transfusion or tattooing. HIV-1 antibody was positive
in 13.6% while 2.3% had detectable HBsAg. HIV-HCV co-
infection was present in 36.2%. Among the STIs, HCV was
signiﬁcantly associated with HSV-2 in 15.5% (OR 2.9, 95%
